Vasodilatory Therapeutics in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort

Tracy Frech^1*, Jessica Gordon^2,3, Lorinda Chung⁴, Marcy Bolster⁵, Barbara Segal⁶, Ann Impens⁷, Lee Shapiro⁸, Avram Goldberg⁹, Vivien Hsu¹⁰, Chris T Derk¹¹, Dinesh Khanna¹², Monique Hinchcliff¹³, Maureen A Murtaugh¹⁴ and Virginia Steen¹⁵

¹Division of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA

²Division of Rheumatology, Department of Internal Medicine, Hospital for Special Surgery, New York, NY, USA

³Division of Rheumatology, Department of Internal Medicine, Weill–Cornell Medical College, New York, NY, USA

⁴Division of Rheumatology, Departments of Medicine and Dermatology, Stanford University, Stanford, CA, USA

⁵Division of Rheumatology, Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USA

⁶Department of Medicine, University of Minnesota and the Hennepin County Medical Center, USA

⁷Department of Internal Medicine, Midwestern University, Downers Grove, IL, USA

⁸The Center for Rheumatology, Saratoga Springs, NY, USA

⁹Division of Rheumatology, Department of Medicine, North Shore-LIJ Health System, NY, USA

¹⁰UMDNJ Scleroderma Program, New Brunswick, NJ, USA

¹¹Division of Rheumatology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

¹²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

¹³Division of Rheumatology, Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

¹⁴Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA

¹⁵Division of Rheumatology, Department of Internal Medicine, Georgetown University, Washington, DC, USA

^*Corresponding Author: Tracy Frech, MD, MS, University of Utah, Salt Lake City, UT, USA, Tel: 801 581 4333, Fax: 801 581 6069 Email: